Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 5;24(1):193.
doi: 10.1186/s12894-024-01582-w.

Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019

Zhenyang Ye  1   2 , Jiahao Wang  2 , Yunfei Xiao  2 , Jinyang Luo  1   2 , Lijing Xu  1   2 , Zaizhi Chen  3
Affiliations

Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019

Zhenyang Ye et al. BMC Urol. .

Abstract

Background: Benign prostatic hyperplasia (BPH) is a prevalent urological disease in elderly males. However, few studies have estimated the temporal and spatial distributions of the BPH burden in male adults aged 60 years and over at the global, national, and regional scales.

Methods: Leveraging the Global Burden of Disease, Injuries, and Risk Factors Study, we estimated the global epidemiological trends in the prevalence, incidence, and disability-adjusted life-years (DALYs) of BPH in 204 countries and 21 regions and 5 sociodemographic index (SDI) regions in males aged 60 years and over between 1990 and 2019. The average annual percentage changes (AAPCs) in age-specific rates were estimated to quantify overall trends. We estimated the contribution of population aging and epidemiological alterations in disease burden via composition analysis.

Results: Over the past three decades, the global prevalent cases, incident cases and DALYs of BPH have increased, ranging from 118.78 to 121.22%. The global number of prevalent BPH cases reached 79 million in people aged 60 years and older in 2019. The prevalence, incidence, and DALYs rates gradually increased, with AAPCs of 0.02, 0.02, and 0.01, respectively. Low-middle, middle, and low SDI regions experienced rapid increases in the number of prevalent cases of BPH. In 2019, China, India, and United States of America bore the largest burden of prevalent cases among people aged 60 years and over. The three regions with the highest prevalence rates of BPH were Eastern Europe, Central Latin America, and Andean Latin America. The increased prevalence was attributed to population growth (94.93%), epidemiological changes (3.45%), and aging (1.62%), globally.

Conclusions: BPH is a global health issue that imposes substantial economic burdens on most countries, particularly males aged 60 years and over. Effective health decisions are imperative for BPH prevention and treatment.

Keywords: Benign prostatic hyperplasia; Disability-adjusted life-years; Global disease burden; Incidence; Prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Global map of 2019 prevalence, incidence, and DALYs of BPH from 1990 to 2019. The 2019 prevalence (A), incidence (B), and DALYs (C) in older adults aged 60–89 years from 1990 to 2019 were shown, respectively. BPH: benign prostatic hyperplasia
Fig. 2
Fig. 2
Joinpoint regression analysis of global BPH. The prevalence (A), incidence (B), and DALYs (C) in older adults aged 60–89 years from 1990 to 2019 were described, respectively. BPH: benign prostatic hyperplasia
Fig. 3
Fig. 3
Decomposition analysis of global and SDI-specific BPH. The prevalence, incidence and DALYs in older adults aged 60–89 years from 1990 to 2019 were shown in this plot. SDI: sociodemographic index. BPH: benign prostatic hyperplasia
Fig. 4
Fig. 4
The prevalence, incidence, and DALYs of BPH across different age groups in 2019. The prevalence (A), incidence (B), and DALYs (C) in older adults with 60–64 years, 60–89 years, 65–69 years, 70–74 years, 75–79 years, 80–84 years and 85–89 years in 2019 were described, respectively. BPH: benign prostatic hyperplasia
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cornu JN, Oelke M, Parsons KF. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(17):1668. author reply 1668-9. 10.1056/NEJMc1209907 - DOI - PubMed
    1. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403–15. 10.1016/j.ucl.2009.07.003 - DOI - PubMed
    1. Fusco F, Creta M, De Nunzio C, et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18(1):15. 10.1186/s12894-018-0329-4 - DOI - PMC - PubMed
    1. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803. 10.1016/j.juro.2011.01.074 - DOI - PubMed
    1. Collaborators GBDBPH. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754–76. 10.1016/S2666-7568(22)00213-6 - DOI - PMC - PubMed

LinkOut - more resources